Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
LXEO Stock Forecast 2025-2026
$4.24
Current Price
$140.73M
Market Cap
Buy 7
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to LXEO Price Targets
+560.4%
To High Target of $28.00
+371.7%
To Median Target of $20.00
+135.8%
To Low Target of $10.00
LXEO Price Momentum
+7.6%
1 Week Change
+20.1%
1 Month Change
-73.0%
1 Year Change
-35.6%
Year-to-Date Change
-78.3%
From 52W High of $19.50
+192.4%
From 52W Low of $1.45
📊 TOP ANALYST CALLS
Did LXEO Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Lexeo Therapeutics is one of their latest high-conviction picks.
Latest LXEO Stock Price Targets & Analyst Predictions
Based on our analysis of 8 Wall Street analysts, LXEO has a bullish consensus with a median price target of $20.00 (ranging from $10.00 to $28.00). The overall analyst rating is Strong Buy (9.1/10). Currently trading at $4.24, the median forecast implies a 371.7% upside. This outlook is supported by 7 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Brian Skorney at Baird, projecting a 560.4% upside. Conversely, the most conservative target is provided by Tessa Romero at JP Morgan, suggesting a 135.8% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
LXEO Analyst Ratings
7
Buy
0
Hold
0
Sell
LXEO Price Target Range
Low
$10.00
Average
$20.00
High
$28.00
Current: $4.24
Latest LXEO Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for LXEO.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 30, 2025 | JP Morgan | Tessa Romero | Overweight | Maintains | $10.00 |
| May 16, 2025 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Maintains | $15.00 |
| May 13, 2025 | Chardan Capital | Geulah Livshits | Buy | Maintains | $20.00 |
| Apr 8, 2025 | Chardan Capital | Geulah Livshits | Buy | Maintains | $22.00 |
| Apr 8, 2025 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Reiterates | $23.00 |
| Mar 26, 2025 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Reiterates | $23.00 |
| Mar 25, 2025 | Chardan Capital | Geulah Livshits | Buy | Maintains | $25.00 |
| Mar 25, 2025 | RBC Capital | Luca Issi | Outperform | Maintains | $20.00 |
| Mar 24, 2025 | Leerink Partners | Mani Foroohar | Outperform | Maintains | $18.00 |
| Jan 21, 2025 | RBC Capital | Luca Issi | Outperform | Reiterates | $24.00 |
| Nov 14, 2024 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Maintains | $23.00 |
| Nov 13, 2024 | Leerink Partners | Mani Foroohar | Outperform | Maintains | $19.00 |
| Nov 13, 2024 | Chardan Capital | Geulah Livshits | Buy | Maintains | $25.00 |
| Oct 31, 2024 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Reiterates | $21.00 |
| Oct 30, 2024 | Chardan Capital | Geulah Livshits | Buy | Maintains | $23.00 |
| Oct 25, 2024 | Chardan Capital | Geulah Livshits | Buy | Maintains | $23.00 |
| Aug 14, 2024 | Chardan Capital | Geulah Livshits | Buy | Maintains | $23.00 |
| Aug 13, 2024 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Maintains | $21.00 |
| Aug 13, 2024 | RBC Capital | Luca Issi | Outperform | Reiterates | $24.00 |
| Jul 16, 2024 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Reiterates | $22.00 |
Lexeo Therapeutics Inc. (LXEO) Competitors
The following stocks are similar to Lexeo Therapeutics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Lexeo Therapeutics Inc. (LXEO) Financial Data
Lexeo Therapeutics Inc. has a market capitalization of $140.73M with a P/E ratio of 0.0x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -80.7%.
Valuation Metrics
Market Cap
$140.73M
Enterprise Value
$50.29M
P/E Ratio
0.0x
PEG Ratio
-1.5x
Price/Sales
0.0x
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+70.9%
Current Ratio
3.4x
Debt/Equity
10.7x
ROE
-80.7%
ROA
-42.9%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Lexeo Therapeutics Inc. (LXEO) Business Model
About Lexeo Therapeutics Inc.
What They Do
Develops innovative genetic therapies for complex diseases.
Business Model
Lexeo Therapeutics generates revenue through the development and commercialization of genetic therapies aimed at treating complex diseases with limited options. The company focuses on precision medicine, targeting specific genetic disorders in fields such as cardiology, ophthalmology, and neurodegenerative diseases.
Additional Information
Established to transform lives through advancements in gene therapy, Lexeo Therapeutics leverages advanced technologies to pioneer treatments that correct or replace defective genes. The company holds a unique position in the biotechnology industry, contributing to the evolution of healthcare solutions and biopharmaceutical innovation.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
75
CEO
Mr. R. Nolan Townsend
Country
United States
IPO Year
N/A
Website
www.lexeotx.comLexeo Therapeutics Inc. (LXEO) Latest News & Analysis
Latest News
Quick Summary
Lexeo Therapeutics has secured $80 million in equity financing to support the development of innovative genetic treatments for cardiovascular diseases.
Why It Matters
Lexeo's $80 million equity financing signals strong investor confidence and funding for innovative treatments, potentially increasing its market position and future profitability in the biotech sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Lexeo Therapeutics Reports First Quarter 2025 Financial Results and Operational Highlights
1 month ago
Quick Summary
Lexeo Therapeutics announced positive interim data for LX2006 in FA cardiomyopathy, exceeding targets. A registrational study is set for early 2026. The company has $106.9M in cash to fund operations into 2027.
Why It Matters
Positive interim data for LX2006 suggests potential for a breakthrough treatment in FA cardiomyopathy, enhancing investor confidence in Lexeo Therapeutics' future and market position.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Lexeo Therapeutics reported positive interim data from its phase 1/2 SUNRISE-FA study on LX2006 for Friedreich's Ataxia Cardiomyopathy. A pivotal study is set for 2026, with market potential of $3.49 billion by 2034.
Why It Matters
Positive interim data boosts investor confidence in Lexeo's potential, suggesting strong market opportunity in a growing $3.49 billion sector, with pivotal study timelines indicating future valuation growth.
Source: Seeking Alpha
Market Sentiment:
Positive
Quick Summary
Lexeo Therapeutics (Nasdaq: LXEO) will present new data on its AAV manufacturing approach at the ASGCT Annual Meeting from May 13-17, 2025, highlighting high yield and quality.
Why It Matters
Positive data on AAV manufacturing could enhance Lexeo's credibility and attract investment, potentially boosting stock value and interest in its treatments for cardiovascular diseases.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Lexeo Therapeutics, Inc. (LXEO) has released interim data for LX2006, targeting Friedreich ataxia cardiomyopathy, a serious heart condition in patients with this rare disorder.
Why It Matters
Lexeo Therapeutics' interim data on LX2006 for Friedreich ataxia cardiomyopathy could signal potential breakthroughs in treatment, impacting the company's stock value and investor sentiment.
Source: Benzinga
Market Sentiment:
Positive
Quick Summary
Lexeo Therapeutics reported positive interim Phase 1/2 data for LX2006, targeting Friedreich Ataxia Cardiomyopathy, indicating readiness to advance to a registrational study.
Why It Matters
Positive interim data for LX2006 indicates potential for successful treatment in Friedreich Ataxia Cardiomyopathy, enhancing Lexeo's market position and possibly driving stock value higher.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About LXEO Stock
What is Lexeo Therapeutics Inc.'s (LXEO) stock forecast for 2025?
Based on our analysis of 8 Wall Street analysts, Lexeo Therapeutics Inc. (LXEO) has a median price target of $20.00. The highest price target is $28.00 and the lowest is $10.00.
Is LXEO stock a good investment in 2025?
According to current analyst ratings, LXEO has 7 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $4.24. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for LXEO stock?
Wall Street analysts predict LXEO stock could reach $20.00 in the next 12 months. This represents a 371.7% increase from the current price of $4.24. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Lexeo Therapeutics Inc.'s business model?
Lexeo Therapeutics generates revenue through the development and commercialization of genetic therapies aimed at treating complex diseases with limited options. The company focuses on precision medicine, targeting specific genetic disorders in fields such as cardiology, ophthalmology, and neurodegenerative diseases.
What is the highest forecasted price for LXEO Lexeo Therapeutics Inc.?
The highest price target for LXEO is $28.00 from Brian Skorney at Baird, which represents a 560.4% increase from the current price of $4.24.
What is the lowest forecasted price for LXEO Lexeo Therapeutics Inc.?
The lowest price target for LXEO is $10.00 from Tessa Romero at JP Morgan, which represents a 135.8% increase from the current price of $4.24.
What is the overall LXEO consensus from analysts for Lexeo Therapeutics Inc.?
The overall analyst consensus for LXEO is bullish. Out of 8 Wall Street analysts, 7 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $20.00.
How accurate are LXEO stock price projections?
Stock price projections, including those for Lexeo Therapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 19, 2025 5:27 PM UTC